Position Paper| Volume 106, P45-53, January 2019

European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer

Published:November 21, 2018DOI:


      • Genetic tests that predict breast cancer risk are now widely available.
      • The results of such tests can be complex and misinterpreted.
      • Tests must be interpreted by appropriate healthcare professionals.
      • Informed consent and counselling must be available.
      • Awareness of tests and referrals must be promoted among healthcare professionals.


      European Breast Cancer Council manifesto and supporting article on genetic risk prediction testing in breast cancer, presented at the 11th European Breast Cancer Conference in Barcelona, Spain.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jolie A.
        My medical choice.
        New York Times, 14 May, 2013
        • Raphael J.
        • Verma S.
        • Hewitt P.
        • Eisen A.
        The impact of Angelina Jolie (AJ)’s story on genetic referral and testing at an academic cancer centre in Canada.
        J Genet Counsel. 2016; 25: 1309-1316
        • Evans D.G.
        • Barwell J.
        • Eccles D.M.
        • Collins A.
        • Izatt L.
        • Jacobs C.
        • et al.
        The Angelina Jolie effect: how high celebrity profile can have major impact on provision of cancer related services.
        Breast Cancer Res. 2014; 16: 442
        • Freedman R.
        • Mountain H.
        • Karina D.
        • Schofield L.
        A retrospective exploration of the impact of the ‘Angelina Jolie effect’ on the single state-wide familial cancer program in Perth, Western Australia.
        J Genet Counsel. 2017; 26: 52-62
        • Cardoso F.
        • Cataliotti L.
        • Costa A.
        • Knox S.
        • Marotti L.
        • Rutgers E.
        • et al.
        European breast cancer conference manifesto on breast centres/units.
        Eur J Cancer. 2017; 72: 244-250
        • Maxwell K.N.
        • Domchek S.M.
        • Nathanson K.L.
        • Robson M.E.
        Population frequency of germline BRCA1/2 mutations.
        J Clin Oncol. 2016; 34: 4183-4185
      1. National Cancer Institute. BRCA mutations: cancer risk and genetic testing.

        • Winters S.
        • Martin C.
        • Murphy D.
        • Shokar N.K.
        Approaches to understanding breast cancer.
        1st ed. Chapter one – breast cancer epidemiology, prevention and screening. 151. Academic Press, 2017
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • Phillips K.A.
        • Mooij T.M.
        • Roos-Blom M.J.
        • et al.
        Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        JAMA. 2017; 317: 2402-2416
        • Slavin T.P.
        • Maxwell K.N.
        • Lilyquist J.
        • Vijai J.
        • Neuhausen S.L.
        • Hart S.N.
        • et al.
        The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.
        NPJ Breast Cancer. 2017; 3: 22
        • National Institute for Health and Care Excellence (NICE)
        Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.
        Clinical guideline [CG164], 2017
        • Rodriguez J.L.
        • Thomas C.C.
        • Massetti G.M.
        • Duquette D.
        • Avner L.
        • Iskander J.
        CDC grand rounds: family history and genomics as tools for cancer prevention and control.
        Morb Mortal Wkly Rep. 2016; 65: 1291-1294
      2. NHS England. Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations. E01/P/b.

      3. Peshkins BN, Isaacs C. Prevalence of BRCA1 and BRCA2 mutations and associated cancer risks. UpToDate 2018.

        • Janavičius R.
        Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
        EPMA J. 2010; 1: 397-412
        • Apessos A.
        • Agiannitopoulos K.
        • Pepe G.
        • Tsaousis G.N.
        • Papadopoulou E.
        • Metaxa-Mariatou V.
        • et al.
        Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.
        Cancer Genet. 2018; 220: 1-12
        • Matthijs G.
        • Souche E.
        • Alders M.
        • Corveleyn A.
        • Eck S.
        • Feenstra I.
        • et al.
        Guidelines for diagnostic next-generation sequencing.
        Eur J Hum Genet. 2016; 24: 1515
        • Wallace A.J.
        New challenges for BRCA testing: a view from the diagnostic laboratory.
        Eur J Hum Genet. 2016; 24: S10-S18
        • Ellison G.
        • Wallace A.
        • Kohlmann A.
        • Patton S.
        A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories.
        Br J Cancer. 2017; 117: 710-716
        • Manchanda R.
        • Patel S.
        • Gordeev V.S.
        • Antoniou A.C.
        • Smith S.
        • Lee A.
        • et al.
        Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women.
        J Natl Cancer Inst. 2018;Jan 18;
        • Wise J.
        Young women with BRCA mutation can safely postpone radical surgery.
        BMJ. 2018; 360: k180
        • US Food and Drug Administration
        • 23andMe, Inc
        Warning letter.
        Nov 22 2013
        • Dohany L.
        • Gustafson S.
        • Ducaine W.
        • Zakalik D.
        Psychological distress with direct-to-consumer genetic testing: a case report of an unexpected BRCA positive test result.
        J Genet Counsel. 2012; 21: 399-401
        • Thompson E.R.
        • Rowley S.M.
        • Li N.
        • McInerny S.
        • Devereux L.
        • Wong-Brown M.W.
        • et al.
        Panel testing for familial breast cancer: calibrating the tension between research and clinical care.
        J Clin Oncol. 2016; 34: 1455-1459
        • Evans D.G.
        • Brentnall A.
        • Byers H.
        • Harkness E.
        • Stavrinos P.
        • Howell A.
        • et al.
        The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
        J Med Genet. 2017; 54: 111-113
        • Tandy-Connor S.
        • Guiltinan J.
        • Krempely K.
        • LaDuca H.
        • Reineke P.
        • Gutierrez S.
        • et al.
        False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.
        Genet Med. 2018;Mar 22;
        • Federal Trade Commission
        DNA test kits: consider the privacy implications.
        December 12 2017
        • Bever L.
        ‘Damaged for the rest of my life’: Woman says surgeons mistakenly removed her breasts and uterus.
        Washington Post, Oct 24 2017
        • Welsh J.L.
        • Hoskin T.L.
        • Day C.N.
        • Thomas A.S.
        • Cogswell J.A.
        • Couch F.J.
        • et al.
        Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes.
        Ann Surg Oncol. 2017; 24: 3067-3072
        • Royal Marsden NHS Foundation Trust
        A beginner's guide to BRCA1 and BRCA2.
        • Middleton A.
        • Mendes A.
        • Benjamin C.M.
        • Howard H.C.
        Direct-to-consumer genetic testing: where and how does genetic counseling fit?.
        Personalised Med. 2017; 14
        • Wilson A.R.
        • Marotti L.
        • Bianchi S.
        • Biganzoli L.
        • Claassen S.
        • Decker T.
        • et al.
        Eur J Cancer. 2013; 49: 3579-3587
        • European Commission
        European quality assurance scheme for breast cancer services: scope.
        • Szender J.B.
        • Kaur J.
        • Clayback K.
        • Hutton M.L.
        • Mikkelson J.
        • Odunsi K.
        • et al.
        Breadth of genetic testing selected by patients at risk of hereditary breast and ovarian cancer.
        Int J Gynecol Canc. 2018; 28: 26-33
        • Faulty BRCA1 O'Quigley J.
        BRCA2 genes: how poor is the prognosis?.
        Ann Epidemiol. 2017; 27: 672-676
        • Derbez B.
        • de Pauw A.
        • Stoppa-Lyonnet D.
        • de Montgolfier S.
        Supporting disclosure of genetic information to family members: professional practice and timelines in cancer genetics.
        Fam Cancer. 2017; 16: 447-457
        • Katapodi M.C.
        • Viassolo V.
        • Caiata-Zufferey M.
        • Nikolaidis C.
        • Bührer-Landolt R.
        • Buerki N.
        • et al.
        Cancer predisposition cascade screening for hereditary breast/ovarian cancer and lynch syndromes in Switzerland: study protocol.
        JMIR Res Protoc. 2017; 6: e184
        • Lobo M.
        • López-Tarruella S.
        • Luque S.
        • Lizarraga S.
        • Flores-Sánchez C.
        • Bueno O.
        • et al.
        Evaluation of breast cancer patients with genetic risk in a university hospital: before and after the implementation of a heredofamilial cancer unit.
        J Genet Counsel. 2017;Dec 15;
        • Skop M.
        • Lorentz J.
        • Jassi M.
        • Vesprini D.
        • Einstein G.
        ‘Guys don't have breasts’: the lived experience of men who have BRCA gene mutations and are at risk for male breast cancer.
        Am J Men's Health. 2018 Feb 5;
      4. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU.

        • GeneWatch UK
        The EU's In Vitro Diagnostics (IVD) regulation: a summary of the regulatory requirements for software and genetic tests.
        December 2017
        • Kalokairinou L.
        • Howard H.C.
        • Slokenberga S.
        • Fisher E.
        • Flatscher-Thöni M.
        • Hartlev M.
        • et al.
        Legislation of direct-to-consumer genetic testing in Europe: a fragmented regulatory landscape.
        J Community Genet. 2017 Nov 18; : 1-16
        • Council of Europe
        Additional protocol to the convention on human rights and biomedicine, concerning genetic testing for health purposes.
      5. European Society of Human Genetics. Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 18(12):1271–1273.

        • Organisation for Economic Co-operation and Development
        OECD guidelines for quality assurance in molecular genetic testing.
        • Soini S.
        Genetic testing legislation in Western Europe – a fluctuating regulatory target.
        J Community Genet. 2012; 3: 143-153
        • Kalokairinou L.
        • Borry P.
        • Howard H.C.
        Regulating the advertising of genetic tests in Europe: a balancing act.
        J Med Genet. 2017; 54: 651-656
        • Covolo L.
        • Rubinelli S.
        • Ceretti E.
        • Gelatti U.
        Internet-based direct-to-consumer genetic testing: a systematic review.
        J Med Internet Res. 2015; 17: e279
        • Warren-Gash C.
        • Krose M.
        • Burton H.
        • Pharoah P.
        Whole genome sequencing in screening for breast cancer.
        PHG Foundation, 2016
        • HM Government, Association of British Insurers
        Concordat and moratorium on genetics and insurance.
        • Moyer V.A.
        • US Preventive Services Task Force
        Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2014; 160: 271-281